These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36248960)

  • 21. Pancreatic neuroendocrine tumors: Nosography, management and treatment.
    Orditura M; Petrillo A; Ventriglia J; Diana A; Laterza MM; Fabozzi A; Savastano B; Franzese E; Conzo G; Santini L; Ciardiello F; De Vita F
    Int J Surg; 2016 Apr; 28 Suppl 1():S156-62. PubMed ID: 26708853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.
    Liu IH; Ford JM; Kunz PL
    Cancer Treat Rev; 2016 Mar; 44():1-9. PubMed ID: 26924193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.
    Ito T; Igarashi H; Jensen RT
    J Gastroenterol; 2012 Sep; 47(9):941-60. PubMed ID: 22886480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A; Bhatt V
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic Neuroendocrine Tumors: State-of-the-Art Diagnosis and Management.
    Lewis A; Li D; Williams J; Singh G
    Oncology (Williston Park); 2017 Oct; 31(10):e1-e12. PubMed ID: 29083468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
    Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR
    J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.
    Pieterman CRC; de Laat JM; Twisk JWR; van Leeuwaarde RS; de Herder WW; Dreijerink KMA; Hermus ARMM; Dekkers OM; van der Horst-Schrivers ANA; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3795-3805. PubMed ID: 28938468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches.
    Stevenson M; Lines KE; Thakker RV
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):525-548. PubMed ID: 30098714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations.
    Liu E; Marincola P; Oberg K
    Therap Adv Gastroenterol; 2013 Sep; 6(5):412-9. PubMed ID: 24003341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine tumors of the pancreas.
    Milan SA; Yeo CJ
    Curr Opin Oncol; 2012 Jan; 24(1):46-55. PubMed ID: 22080942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular alterations in sporadic pancreatic neuroendocrine microadenomas.
    Hadano A; Hirabayashi K; Yamada M; Kawanishi A; Takanashi Y; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
    Pancreatology; 2016; 16(3):411-5. PubMed ID: 26905832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy for metastatic pancreatic neuroendocrine tumors.
    Rossi RE; Massironi S; Conte D; Peracchi M
    Ann Transl Med; 2014 Jan; 2(1):8. PubMed ID: 25332984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan.
    Ito T; Lee L; Hijioka M; Kawabe K; Kato M; Nakamura K; Ueda K; Ohtsuka T; Igarashi H
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):574-7. PubMed ID: 25689058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The genetics of neuroendocrine tumors.
    Öberg K
    Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated clinicopathological features and gene microarray analysis of pancreatic neuroendocrine tumors.
    Zhou H; Chen Q; Tan W; Qiu Z; Li S; Song Y; Gao S
    Gene; 2017 Aug; 625():72-77. PubMed ID: 28479381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
    Arakelyan J; Zohrabyan D; Philip PA
    Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?
    Challis BG; Casey RT; Grossman A; Newell-Price J; Newey P; Thakker RV
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):708-715. PubMed ID: 31505044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium.
    Mafficini A; Scarpa A
    J Endocrinol; 2018 Mar; 236(3):R161-R167. PubMed ID: 29321190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
    Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
    Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.
    Chen SF; Kasajima A; Yazdani S; Chan MS; Wang L; He YY; Gao HW; Sasano H
    Hum Pathol; 2013 Oct; 44(10):2199-203. PubMed ID: 23954140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.